Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host — the formal FAO/WHO 2001 definition, re-endorsed by ISAPP in 2014. The definition requires three elements: the organism must be alive (viable), it must be administered in a dose shown to produce effect, and a specific health benefit must be documented. This framing distinguishes probiotics from generic fermented food consumption.

Common probiotic genera

The most widely studied probiotic organisms belong to: Lactobacillus (now reclassified by Zheng et al. 2020 into 25 genera including Lactiplantibacillus, Lacticaseibacillus, Limosilactobacillus) — widespread in fermented dairy and plant products; Bifidobacterium — dominant commensal in infant gut, present in adult colon; Saccharomyces boulardii — a yeast with documented efficacy in antibiotic-associated and traveler's diarrhea; Enterococcus faecium, Streptococcus thermophilus, Bacillus coagulans — additional probiotic species in various applications.

Strain specificity

A critical concept in probiotic evidence interpretation is strain specificity: health effects are typically demonstrated for specific strains, not for species or genera broadly. Lactobacillus rhamnosus GG (LGG) is a well-characterized strain with multiple supporting trials; this evidence does not transfer automatically to other L. rhamnosus strains. Probiotic product labels specifying only genus or species (e.g., "Lactobacillus acidophilus") without strain designation provide insufficient information for evidence-based use.

Established clinical applications

Clinical conditions with moderate-to-strong evidence of probiotic benefit (per AGA, Cochrane, and other systematic reviews): (1) prevention of antibiotic-associated diarrhea — particularly with Saccharomyces boulardii and Lactobacillus rhamnosus GG; (2) Clostridioides difficile prevention — modest benefit when combined with antibiotics; (3) acute infectious diarrhea in children — shortened duration with specific strains; (4) ulcerative colitis maintenance of remission — VSL#3 (now Visbiome) has been studied; (5) pouchitis — post-colectomy; (6) infant colic — Lactobacillus reuteri DSM 17938 in breast-fed infants; (7) necrotizing enterocolitis prevention in preterm infants.

Mechanisms of action

Proposed mechanisms include: competitive exclusion of pathogens via receptor-site competition and antimicrobial peptide production; strengthening intestinal barrier function via tight junction protein regulation; direct immune modulation through pattern-recognition receptor signaling; short-chain fatty acid production from fermentation; bile acid modification; and neurotransmitter synthesis (GABA, serotonin precursors) relevant to the gut-brain axis.

Probiotics vs. fermented foods

Traditional fermented foods — yogurt, kefir, sauerkraut, kimchi, miso, tempeh, kombucha — contain live microorganisms from spontaneous or starter-culture fermentation but do not necessarily qualify as probiotics. Strain identity is often uncharacterized, dose is inconsistent, and documented health benefits may not apply. The 2020 ISAPP consensus on fermented foods acknowledged their general healthful profile without blanket probiotic status. Consumption of fermented foods contributes to dietary microbial exposure and may have beneficial effects mediated through non-probiotic pathways (polyphenols, bioactive peptides, short-chain fatty acids).

Commercial product quality

Probiotic product quality varies substantially. Concerns include: organism viability at time of consumption (requires appropriate storage, often refrigeration); CFU (colony-forming unit) claims matching actual content; strain identity confirmed (ideally by WGS); shelf-life stability validated. Independent testing by ConsumerLab, NSF, and Clean Label Project has repeatedly identified products with substantially lower CFU than labeled or contaminating organisms.

Dose and formulation

Effective doses typically range from 10^8 to 10^11 CFU per day, with meaningful variation by application and strain. Lower doses may be ineffective; higher doses do not uniformly produce greater effect. Common formulations include capsules, powders, liquid suspensions, and fermented food products. Some strains are genetically modified for enhanced properties (e.g., Lactobacillus lactis engineered to produce IL-10) and are approaching regulatory approval for specific conditions.

Safety

Commercial probiotic products are generally safe in healthy populations. Rare but serious adverse events — bacteremia, fungemia — have occurred in immunocompromised patients, critically ill ICU patients, and individuals with central venous catheters. Probiotic use in these populations warrants clinical caution.